Arena Pharmaceuticals and Eisai have expanded their Belviq (lorcaserin HCl) marketing and supply agreement. The expanded agreement provides Eisai with exclusive worldwide commercialization rights, except in South Korea, Taiwan, Australia, Israel and New Zealand. A previous agreement granted Eisai rights to commercialize Belviq in most of North and South America.    Arena will receive an upfront payment of $60 million and is eligible to receive a total of $176.5 million in regulatory and developm...